Controversies in the locoregional management of head and neck cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 9, Issue 6, 2011, Pages 653-662

  Brizel, David M ^a   Lydiatt, William ^b   Colevas, A Dimitrios ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NEBRASKA MEDICAL CENTER   (United States)

^c STANFORD CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; FLUOROURACIL; GEFITINIB; PACLITAXEL; PANITUMUMAB; ZALUTUMUMAB;

CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; DRUG MEGADOSE; FOLLOW UP; HEAD AND NECK CANCER; HUMAN; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; OROPHARYNX CANCER; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; QUALITY OF LIFE; REVIEW; SYSTEMIC THERAPY;

EID: 79957790651     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2011.0054     Document Type: Review

References (78)

1. Armitage JO. Early-stage Hodgkin's lymphoma. N Engl J Med 2010;363:653-662.
2. Bentzen SM, Rosenthal DI, Weymuller EA, Trotti A. Increasing toxicity in nonoperative head and neck cancer treatment: investigations and interventions. Int J Radiat Oncol Biol Phys 2007;69:S79-82.
3. Bentzen SM, Trotti A. Evaluation of early and late toxicities in chemoradiation trials. J Clin Oncol 2007;25:4096-4103. (Pubitemid 47492954)
4. O'Malley BW Jr, Weinstein GS, Snyder W, Hockstein NG. Transoral robotic surgery (TORS) for base of tongue neoplasms. Laryngoscope 2006;116:1465-1472. (Pubitemid 44181466)
5. Cohen MA, Weinstein GS, O'Malley BW Jr, et al. Transoral robotic surgery and human papillomavirus status: oncologic results. Head Neck 2011;33:573-580.
6. Pfister DG, Ang KK, Brixel D, et al. NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers. Version 2, 2011. Available at: http://www.nccn.org/professionals/physician-gls/pdf/head-and-neck.pdf. Accessed March 31, 2011.
7. Djulbegovic B. The paradox of equipoise: the principle that drives and limits therapeutic discoveries in clinical research. Cancer Control 2009;16:342-347.
8. Djulbegovic B, Cantor A, Clarke M. The importance of preservation of the ethical principle of equipoise in the design of clinical trials: relative impact of the methodological quality domains on the treatment effect in randomized controlled trials. Account Res 2003;10:301-315.
9. Mehta V, Yu GP, Schantz SP. Population-based analysis of oral and oropharyngeal carcinoma: changing trends of histopathologic differentiation, survival and patient demographics. Laryngoscope 2010;120:2203-2212.
10. Hong AM, Dobbins TA, Lee CS, et al. Human papillomavirus predicts outcome in oropharyngeal cancer in patients treated primarily with surgery or radiation therapy. Br J Cancer 2010;103:1510-1517.
11. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363:24-35.
12. Attner P, Du J, Nasman A, et al. Human papillomavirus and survival in patients with base of tongue cancer. Int J Cancer, in press.
13. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008;100:261-269. (Pubitemid 351480538)
14. Allen CT, Lewis JS Jr, El-Mofty SK, et al. Human papillomavirus and oropharynx cancer: biology, detection and clinical implications. Laryngoscope 2010;120:1756-1772.
15. Haughey B. Transoral laser microsurgery as primary treatment of advanced stage oropharyngeal cancer: a United States Multicenter Study [abstract]. Presented at the American Head and Neck Society Meeting; May 27-31, 2009; Phoenix, Arizona. Abstract S032.
16. Wittes RE, Brescia F, Young CW, et al. Combination chemotherapy with cis-diamminedichloroplatinum (II) and bleomycin in tumors of the head and neck. Oncology 1975;32:202-207.
17. Randolph VL, Vallejo A, Spiro RH, et al. Combination therapy of advanced head and neck cancer: induction of remissions with diamminedichloroplatinum (II), bleomycin and radiation therapy. Cancer 1978;41:460-467. (Pubitemid 8289260)
18. Creagan ET, Fountain KS, Frytak S, et al. Concomitant radiation therapy and cis-diamminedichloroplatinum (II) in patients with advanced head and neck cancer. Med Pediatr Oncol 1981;9:119-120. (Pubitemid 11096382)
19. Keizer HJ, Karim AB, Njo KH, et al. Feasibility study on daily administration of cis-diamminedichloroplatinum(II) in combination with radiotherapy. Radiother Oncol 1984;1:227-234.
20. Adelstein DJ, Kalish LA, Adams GL, et al. Concurrent radiation therapy and chemotherapy for locally unresectable squamous cell head and neck cancer: an Eastern Cooperative Oncology Group pilot study. J Clin Oncol 1993;11:2136-2142. (Pubitemid 23332249)
21. Adelstein DJ, Sharan VM, Damm C, et al. Concurrent radiation therapy, 5-fluorouracil, and cisplatin for stage II, III, and IV, node-negative, squamous cell head and neck cancer. Results and surgical implications. Cancer 1992;70:2685-2690.
22. Brizel DM, Leopold KA, Fisher SR, et al. A phase I/II trial of twice daily irradiation and concurrent chemotherapy for locally advanced squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1994;28:213-220.
23. El-Sayed S, Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials. J Clin Oncol 1996;14:838-847. (Pubitemid 26085529)
24. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000;355:949-955.
25. Pignon JP, le Maitre A, Bourhis J. Meta-analyses of chemotherapy in head and neck cancer (MACH-NC): an update. Int J Radiat Oncol Biol Phys 2007;69:S112-114.
26. Pignon JP, le Maitre A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009;92:4-14.
27. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338:1798-1804. (Pubitemid 28277960)
28. Michiels S, Le Maitre A, Buyse M, et al. Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data. Lancet Oncol 2009;10:341-350.
29. Staar S, Rudat V, Stuetzer H, et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy-results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001;50:1161-1171. (Pubitemid 32727792)
30. Budach W, Hehr T, Budach V, et al. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer 2006;6:28.
31. Jeremic B, Shibamoto Y, Milicic B, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 2000;18:1458-1464. (Pubitemid 30205391)
32. Watkins JM, Zauls AJ, Wahlquist AH, et al. Low-dose weekly platinum-based chemoradiation for advanced head and neck cancer. Laryngoscope 2010;120:236-242.
33. Huguenin P, Beer KT, Allal A, et al. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol 2004;22:4665-4673.
34. Gan HK, Bernstein LJ, Brown J, et al. Cognitive functioning after radiotherapy or chemoradiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys, in press.
35. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350:1945-1952. (Pubitemid 38580197)
36. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350:1937-1944.
37. Ang KK. Concurrent radiation chemotherapy for locally advanced head and neck carcinoma: are we addressing burning subjects? J Clin Oncol 2004;22:4657-4659.
38. De Andres L, Brunet J, Lopez-Pousa A, et al. Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer. J Clin Oncol 1995;13:1493-1500.
39. Fountzilas G, Ciuleanu E, Dafni U, et al. Concomitant radiochemotherapy vs radiotherapy alone in patients with head and neck cancer: a Hellenic Cooperative Oncology Group phase III study. Med Oncol 2004;21:95-107. (Pubitemid 39107999)
40. Chitapanarux I, Lorvidhaya V, Kamnerdsupaphon P, et al. Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: randomised, non-inferiority, open trial. Eur J Cancer 2007;43:1399-1406. (Pubitemid 46874069)
41. Homma A, Shirato H, Furuta Y, et al. Randomized phase II trial of concomitant chemoradiotherapy using weekly carboplatin or daily low-dose cisplatin for squamous cell carcinoma of the head and neck. Cancer J 2004;10:326-332. (Pubitemid 44403471)
42. Jeremic B, Shibamoto Y, Stanisavljevic B, et al. Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomized trial. Radiother Oncol 1997;43:29-37. (Pubitemid 27191976)
43. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357:1705-1715. (Pubitemid 350005152)
44. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-578. (Pubitemid 43209104)
45. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11:21-28.
46. Burtness B, Goldwasser MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005;23:8646-8654. (Pubitemid 46211507)
47. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-1127.
48. Chen C, Kane M, Song J, et al. Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer. J Clin Oncol 2007;25:4880-4886. (Pubitemid 350220417)
49. Hainsworth JD, Spigel DR, Burris HA III, et al. Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck. Cancer 2009;115:2138-2146.
50. Van Waes C, Allen CT, Citrin D, et al. Molecular and clinical responses in a pilot study of gefitinib with paclitaxel and radiation in locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2010;77:447-454.
51. ClinicalTrials.gov Web site. Radiation therapy and cisplatin or panitumumab in treating patients with locally advanced stage III or stage IV head and neck cancer. Available at: http://clinicaltrials.gov/ct2/show/ NCT00820248?term=NCT00820248&rank=1. Accessed April 4, 2011.
52. ClinicalTrials.gov Web site. Radiation therapy and cisplatin with or without cetuximab in treating patients with stage III or stage IV head and neck cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT00265941. Accessed April 4, 2011.
53. Catimel G, Verweij J, Mattijssen V, et al. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 1994;5:533-537.
54. Citrin D, Mansueti J, Likhacheva A, et al. Long-term outcomes and toxicity of concurrent paclitaxel and radiotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2009;74:1040-1046.
55. Dreyfuss AI, Clark JR, Norris CM, et al. Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 1996;14:1672-1678. (Pubitemid 26134226)
56. Forastiere AA, Shank D, Neuberg D, et al. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer 1998;82:2270-2274. (Pubitemid 28240836)
57. Geng CX, Zeng ZC, Wang JY, et al. Docetaxel shows radiosensitization in human hepatocellular carcinoma cells. World J Gastroenterol 2005;11:2990-2993.
58. Cmelak AJ, Murphy BA, Burkey B, et al. Taxane-based chemoirradiation for organ preservation with locally advanced head and neck cancer: results of a phase II multi-institutional trial. Head Neck 2007;29:315-324. (Pubitemid 46623496)
59. Jain RK, Kirar P, Gupta G, et al. A comparative study of low dose weekly paclitaxel versus cisplatin with concurrent radiation in the treatment of locally advanced head and neck cancers. Indian J Cancer 2009;46:50-53.
60. Karasawa K, Shinoda H, Katsui K, et al. Radiotherapy with concurrent docetaxel and carboplatin for head and neck cancer. Anticancer Res 2002;22:3785-3788. (Pubitemid 36132866)
61. Sunwoo JB, Herscher LL, Kroog GS, et al. Concurrent paclitaxel and radiation in the treatment of locally advanced head and neck cancer. J Clin Oncol 2001;19:800-811. (Pubitemid 32119096)
62. Tishler RB, Busse PM, Norris CM Jr, et al. An initial experience using concurrent paclitaxel and radiation in the treatment of head and neck malignancies. Int J Radiat Oncol Biol Phys 1999;43:1001-1008. (Pubitemid 29144786)
63. Tishler RB, Norris CM Jr, Colevas AD, et al. A phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck. Cancer 2002;95:1472-1481.
64. Kies MS, Harris J, Rotman M, et al. Phase II randomized trial of postoperative chemoradiation plus cetuximab for high-risk squamous cell carcinoma of the head and neck (RTOG 0234) [abstract]. Int J Radiat Oncol Biol Phys 2009;75(Suppl):S14-15. Abstract 29.
65. Barkley HT Jr, Fletcher GH, Jesse RH, Lindberg RD. Management of cervical lymph node metastases in squamous cell carcinoma of the tonsillar fossa, base of tongue, supraglottic larynx, and hypopharynx. Am J Surg 1972;124:462-467.
66. Argiris A, Stenson KM, Brockstein BE, et al. Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer. Head Neck 2004;26:447-455. (Pubitemid 38569204)
67. Brizel DM, Prosnitz RG, Hunter S, et al. Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2004;58:1418-1423. (Pubitemid 38438302)
68. Yao M, Luo P, Hoffman HT, et al. Pathology and FDG PET correlation of residual lymph nodes in head and neck cancer after radiation treatment. Am J Clin Oncol 2007;30:264-270. (Pubitemid 46884146)
69. Robbins KT, Ferlito A, Suarez C, et al. Is there a role for selective neck dissection after chemoradiation for head and neck cancer? J Am Coll Surg 2004;199:913-916.
70. Stenson KM, Haraf DJ, Pelzer H, et al. The role of cervical lymphadenectomy after aggressive concomitant chemoradiotherapy: the feasibility of selective neck dissection. Arch Otolaryngol Head Neck Surg 2000;126:950-956. (Pubitemid 30658293)
71. Stenson KM, Huo D, Blair E, et al. Planned post-chemoradiation neck dissection: significance of radiation dose. Laryngoscope 2006;116:33-36. (Pubitemid 44383957)
72. Tan A, Adelstein DJ, Rybicki LA, et al. Ability of positron emission tomography to detect residual neck node disease in patients with head and neck squamous cell carcinoma after definitive chemoradiotherapy. Arch Otolaryngol Head Neck Surg 2007;133:435-440. (Pubitemid 46799778)
73. Ong SC, Schoder H, Lee NY, et al. Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for locoregional advanced head and neck cancer. J Nucl Med 2008;49:532-540. (Pubitemid 351520600)
74. Nayak JV, Walvekar RR, Andrade RS, et al. Deferring planned neck dissection following chemoradiation for stage IV head and neck cancer: the utility of PET-CT. Laryngoscope 2007;117:2129-2134. (Pubitemid 351339585)
75. Porceddu SV, Pryor DI, Burmeister E, et al. Results of a prospective study of positron emission tomography-directed management of residual nodal abnormalities in node-positive head and neck cancer after definitive radiotherapy with or without systemic therapy. Head Neck, in press.
76. Hehr T, Classen J, Schreck U, et al. Selective lymph node dissection following hyperfractionated accelerated radio-(chemo-)therapy for advanced head and neck cancer. Strahlenther Onkol 2002;178:363-368. (Pubitemid 34665783)
77. Robbins KT, Clayman G, Levine PA, et al. Neck dissection classification update: revisions proposed by the American Head and Neck Society and the American Academy of Otolaryngology-Head and Neck Surgery. Arch Otolaryngol Head Neck Surg 2002;128:751-758. (Pubitemid 34755299)
78. Clayman GL, Johnson CJ II, Morrison W, et al. The role of neck dissection after chemoradiotherapy for oropharyngeal cancer with advanced nodal disease. Arch Otolaryngol Head Neck Surg 2001;127:135-139. (Pubitemid 32163638)